• Find us on Facebook
  • Follow BMJ OnExamination on Twitter

Latest News

Like this article?

Click vote now

0

Highlights

from JAMA - 23 Jul 14



0

An HIV Cure Feasibility, Discovery, and Implementation

from JAMA - 23 Jul 14

The discovery and deployment of antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection is one of the most extraordinary achievements in recent biomedical history. Between 1996 and 2012, ART averted an estimated 6.6 million AIDS-related deaths worldwide. For HIV-infected individuals with access to ART, life expectancy at diagnosis now approximates that of uninfected individuals—a remarkable feat. These extraordinary successes, however, are tempered by the necessity of lifel



0

Reconsideration of the Lifetime Ban on Blood Donation by Men Who Have Sex With Men

from JAMA - 23 Jul 14

In 2013, the US Supreme Court took a historic step in United States v Windsor by striking down the Defense of Marriage Act on the grounds that it imposed a “disability on the class [of gay Americans] by refusing to acknowledge a status the State finds to be dignified and proper.” This milestone in gay rights stands in stark contrast to the ongoing lifetime ban imposed in 1983 on blood donation by men who have ever had sex with men (MSMs) even once. As it stands, the US Food and Drug Administrati



0

Realization of an AIDS-Free Generation Ensuring Sustainable Treatment for Children

from JAMA - 23 Jul 14

According to a 2011 statement from the Joint United Nations Program on HIV/AIDS (UNAIDS), “by 2015 children everywhere can be born free of HIV and their mothers remain alive.” These ambitious goals were defined to provide renewed energy and to reinvigorate programs to realize the vision of an AIDS-free generation. Since the launch of the Global Plan Toward the Elimination of New HIV Infections Among Children by 2015 and Keeping Their Mothers Alive (focused on 22 countries with the highest estima



0

Maximizing Benefits of New Strategies to Prevent Mother-to-Child HIV Transmission Without Harming Existing Services

from JAMA - 23 Jul 14

Over the past decade, global efforts to prevent mother-to-child human immunodeficiency virus (HIV) transmission have been driven by rapid progress in scientific discovery, policy, and program implementation. One important advance has been the Option B+ strategy to provide lifelong antiretroviral therapy (ART) to all HIV-infected women identified during pregnancy or breastfeeding. Initially developed as a strategy for settings in which CD4 T-lymphocyte testing was not available, Option B+ is now



0

Water, Water, Everywhere

from JAMA - 23 Jul 14

“Doc, they’re not giving me my Benadryl.” The patient scraped his long fingernails along his neck to emphasize the point, his skin falling in tiny flakes onto his dark green uniform. The space where he used to have eyebrows lifted quizzically, awaiting my response.




0

Quantum Leaps, Microeconomics, and the Treatment of Patients With Hepatitis C and HIV Coinfection

from JAMA - 23 Jul 14

Until very recently, patients with hepatitis C virus (HCV) infection were treated with pegylated-interferon administered weekly by subcutaneous injection plus ribavirin given orally twice daily. Over the last decade, however, by virtue of development of directly acting agents, therapy for hepatitis C infection has advanced by several orders of magnitude, creating a transformative and unprecedented revolution.



0

Integrating HIV Prevention Into Practice

from JAMA - 23 Jul 14

At the beginning of the human immunodeficiency virus (HIV) epidemic 30 years ago, the main methods for prevention were clean needles and condoms. Even though these available methods would work, their success was completely dependent on human behavior. However, over the past decade, biomedical prevention of HIV has come of age, in the wake of the extraordinary success of antiretroviral therapy (ART) for treatment of the HIV-infected person. In quick succession, effective approaches for prevention



0

HIV/AIDS: Gaining Ground and Forging Forward

from JAMA - 23 Jul 14

The physician and scientist Galen (born in the second century) endeavored to consider all possible implications when pondering a problem. “Reason,” he wrote, “finds the answers most quickly, but experience confirms our confidence in them.”



0

Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection

from JAMA - 23 Jul 14

ImportanceTreatment of hepatitis C virus (HCV) infection in patients also infected with human immunodeficiency virus (HIV) has been limited due to drug interactions with antiretroviral therapies (ARTs) and the need to use interferon. ObjectiveTo determine the rates of HCV eradication (sustained virologic response [SVR]) and adverse events in patients with HCV-HIV coinfection receiving sofosbuvir and ribavirin treatment.Design, Setting, and ParticipantsOpen-label, nonrandomized, uncontrolled phas



0

Pregnancy Incidence and Outcomes Among Women Receiving Preexposure Prophylaxis for HIV Prevention A Randomized Clinical Trial

from JAMA - 23 Jul 14

ImportanceAntiretroviral preexposure prophylaxis (PrEP), using tenofovir disoproxil fumarate (TDF) and combination emtricitabine/tenofovir disoproxil fumarate (FTC+TDF), is efficacious for prevention of human immunodeficiency virus (HIV) acquisition. PrEP could reduce periconception HIV risk, but the effect on pregnancy outcomes is not well defined.ObjectiveTo assess pregnancy incidence and outcomes among women using PrEP during the periconception period.Design, Setting, and ParticipantsRandomiz



0

Effect of Optional Home Initiation of HIV Care Following HIV Self-testing on Antiretroviral Therapy Initiation Among Adults in Malawi A Randomized Clinical Trial

from JAMA - 23 Jul 14

ImportanceSelf-testing for HIV infection may contribute to early diagnosis of HIV, but without necessarily increasing antiretroviral therapy (ART) initiation.ObjectiveTo investigate whether offering optional home initiation of HIV care after HIV self-testing might increase demand for ART initiation, compared with HIV self-testing accompanied by facility-based services only.Design, Setting, and ParticipantsCluster randomized trial conducted in Blantyre, Malawi, between January 30 and November 5,



0

Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation A Randomized Clinical Trial

from JAMA - 23 Jul 14

ImportanceAmong patients infected with human immunodeficiency virus (HIV), visceral adiposity is associated with metabolic dysregulation and ectopic fat accumulation. Tesamorelin, a growth hormone–releasing hormone analog, specifically targets visceral fat reduction but its effects on liver fat are unknown.ObjectiveTo investigate the effect of tesamorelin on visceral and liver fat.Design, Setting, and PatientsDouble-blind, randomized, placebo-controlled trial conducted among 50 antiretroviral-tr



0

HIV Prevention in Clinical Care Settings 2014 Recommendations of the International Antiviral Society–USA Panel

from JAMA - 23 Jul 14

ImportanceEmerging data warrant the integration of biomedical and behavioral recommendations for human immunodeficiency virus (HIV) prevention in clinical care settings.ObjectiveTo provide current recommendations for the prevention of HIV infection in adults and adolescents for integration in clinical care settings.Data Sources, Study Selection, and Data SynthesisData published or presented as abstracts at scientific conferences (past 17 years) were systematically searched and reviewed by the In



0

Antiretroviral Treatment of Adult HIV Infection 2014 Recommendations of the International Antiviral Society–USA Panel

from JAMA - 23 Jul 14

ImportanceNew data and antiretroviral regimens expand treatment choices in resource-rich settings and warrant an update of recommendations to treat adults infected with human immunodeficiency virus (HIV).ObjectiveTo provide updated treatment recommendations for adults with HIV, emphasizing when to start treatment; what treatment to start; the use of laboratory monitoring tools; and managing treatment failure, switches, and simplification.Data Sources, Study Selection, and Data SynthesisAn Intern




0

Dolutegravir (Tivicay) for HIV

from JAMA - 23 Jul 14

The FDA has approved dolutegravir (doll-you-TEG-rah-veer; Tivicay – Viiv Healthcare), an integrase strand transfer inhibitor (INSTI), for treatment of HIV-1 infection in adults and in children =12 years old who weigh at least 40 kg. It is the third INSTI to be approved by the FDA; raltegravir and elvitegravir were approved earlier (Table 1).



0

Trends in Diagnoses of HIV Infection in the United States, 2002-2011

from JAMA - 23 Jul 14

There has been increasing emphasis on care and treatment for persons with human immunodeficiency virus (HIV) in the United States during the past decade, including the use of antiretroviral therapy for increasing survival and decreasing transmission. Accurate HIV diagnosis data recently became available for all states, allowing for the first time an examination of long-term national trends. These data can be used to monitor awareness of serostatus among persons living with HIV, primary preventio



0

Evaluating a Multipayer Medical Home Intervention

from JAMA - 23 Jul 14

To the Editor As physicians involved in the Pennsylvania Chronic Care Initiative (PACCI), a medical home pilot, we are concerned that the evaluation of the first phase had many inadequacies that steered Dr Friedberg and colleagues to the wrong conclusions. These conclusions have the potential to impede further payment reform and block continued redesign of primary care practices.



0

Evaluating a Multipayer Medical Home Intervention

from JAMA - 23 Jul 14

To the Editor Dr Friedberg and colleagues analyzed a multipayer medical home intervention and failed to demonstrate meaningful outcomes. We performed a rigorous mixed-methods evaluation of the same PACCI through on-site observations and interviewing 118 individuals (clinicians, staff, and administrators) at 17 of the 25 participating primary care practices in the PACCI. We believe our evaluation provides important insights into the challenges of translating the PACCI into meaningful outcomes.



0

Evaluating a Multipayer Medical Home Intervention

from JAMA - 23 Jul 14

To the Editor We participated in the southwestern Pennsylvania version of the PACCI and achieved level 3 NCQA PCMH recognition. Contrary to the findings of Dr Friedberg and colleagues, our practice did find a significant decrease in low-density lipoprotein cholesterol and systolic blood pressure levels in 126 patients with diabetes who were aged 18 to 75 years over the 18-month period from 2009 to 2011, when we achieved level 3 PCMH recognition. However, no change was noted in high-density lipop



0

Evaluating a Multipayer Medical Home Intervention—Reply

from JAMA - 23 Jul 14

In Reply Drs Valko and Wender suggest that a 3-year time horizon may be too short to observe changes in health care costs and utilization, reporting that in their medical home practice these changes occurred later. It is certainly possible that reducing costs and excess health care utilization may require sustained changes and longer observation periods. Continued evaluations are needed.



0

Liver Transplants Among US Veterans

from JAMA - 23 Jul 14

To the Editor Dr Goldberg and colleagues reported a disparity in the rates of US veterans waitlisted for liver transplantation and, once waitlisted, receiving a liver transplant when the veteran’s local Veteran’s Affairs (VA) medical center was located more than 100 miles from a transplant center. This disparity was observed regardless of whether the veteran received care at a Veterans Affairs Transplant Center (VATC) or a non-VATC. I believe that the authors imply that distance relationships af



0

Liver Transplants Among US Veterans—Reply

from JAMA - 23 Jul 14

In Reply We concur with Dr Gunnar that distance-related inequities in access to liver transplantation are not unique to the VHA. However, the absence of robust national databases precludes such evaluations in the non-VA population. The VHA’s integrated electronic medical record allowed us to use the VHA as a model of the effects of centralization and there was no intent to imply that these are VHA-specific disparities. Unlike private centers, the VHA attempts to minimize the additional burden of


 

1044 items Page 1 of 42 1 2 3 4 5 6 7 8 9 10 >>

    Search

    Categories

    Keyword cloud

    abstract blood brain cardiac cardiovascular chronic CI diabetes dog England genetic HIV included injury kidney Lancet myocardial participants performed protein randomized screening supplied UK volume

    Top news voters

    ajaykuks1 vote

    © 2014 BMJ Publishing Group Ltd . All rights reserved.